전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved75 programs
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting
AntibodyLimited DatastaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Ruijin
Trials 1Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#Non-squamousNon-smallCellLungCan+2
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCancer+3
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Vebrekotuzumab (Vebrekotuzumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleInflaRx GmbHPhase 2

Vilobelimab (Vilobelimab)

SCC - Squamous Cell Carcinoma of Skin · SCC - Squamous Cell Carcinoma of Skin

#SCC-SquamousCellCarcinomaofSkin#Antibody#Phase2#monoclonal-antibody#InflaRx
Trials 1Status Discontinued
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+1
Trials 1Status Active
AntibodyLimited DatastaleCancer Institute and Hospital, …Phase 2

cadonilimab，bevacizumab，docetaxel (cadonilimab，bevacizumab，docetaxel)

Stage IVB Lung Cancer; Non-Squamous · Stage IVB Lung Cancer

#StageIVBLungCancer#Antibody#Phase2#monoclonal-antibody#Non-Squamous+1
Trials 1Status Recruiting
AntibodyLimited DatastaleVaccinex Inc.Phase 2

pembrolizumab (Keytruda, pepinemab + pembrolizumab)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) · Recurrent/Metastatic Squamous Cell Carci

#RecurrentMetastaticSquamousCellC#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active

4 / 4 pages

← PreviousNext →